NCT01515969View on ClinicalTrials.gov

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2014

Conditions
Non-small Cell Lung Cancer (NSCLC), RecurrentNon-small Cell Lung Cancer (NSCLC), Stage IV
Interventions
DRUG

Erlotinib hydrochloride

Given PO

DRUG

Dovitinib lactate

Given PO

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors

Collaborators (2)

Genentech, Inc.
Novartis
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Heather Wakelee

OTHER

NCT01515969 - Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter